IDEXX Laboratories (IDXX) is a publicly traded Healthcare sector company. As of August 7, 2026, IDXX trades at $580.65 with a market cap of $46.39B and a P/E ratio of 42.47. IDXX moved -1.01% today. Year to date, IDXX is -13.56%; over the trailing twelve months it is -8.90%. Its 52-week range spans $356.14 to $769.98. Analyst consensus is buy with an average price target of $710.40. Rallies surfaces IDXX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for IDXX, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $580.65 |
| Market Cap | $46.39B |
| P/E Ratio | 42.47 |
| EPS | $13.69 |
| Dividend Yield | 0.00% |
| 52-Week High | $769.98 |
| 52-Week Low | $356.14 |
| Volume | 95.14K |
| Avg Volume | 0 |
| Revenue (TTM) | $4.45B |
| Net Income | $1.10B |
| Gross Margin | 62.05% |
6 analysts cover IDXX: 0 strong buy, 4 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $710.40.